These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10754226)

  • 1. The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta.
    Gantier R; Gilbert D; Dumanchin C; Campion D; Davoust D; Toma F; Frébourg T
    Neurosci Lett; 2000 Apr; 283(3):217-20. PubMed ID: 10754226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that the beta-catenin nuclear translocation assay allows for measuring presenilin 1 dysfunction.
    Van Gassen G; De Jonghe C; Nishimura M; Yu G; Kuhn S; St George-Hyslop P; Van Broeckhoven C
    Mol Med; 2000 Jul; 6(7):570-80. PubMed ID: 10997338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop.
    Gantier R; Dumanchin C; Campion D; Loutelier C; Lange C; Gagnon J; Davoust D; Frébourg T; Toma F
    Neuroreport; 1999 Sep; 10(14):3071-4. PubMed ID: 10549825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.
    Takashima A; Murayama M; Murayama O; Kohno T; Honda T; Yasutake K; Nihonmatsu N; Mercken M; Yamaguchi H; Sugihara S; Wolozin B
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9637-41. PubMed ID: 9689133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau phosphorylation in cells transfected with wild-type or an Alzheimer's disease mutant Presenilin 1.
    Irving NG; Miller CC
    Neurosci Lett; 1997 Jan; 222(2):71-4. PubMed ID: 9111731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.
    Campion D; Dumanchin C; Hannequin D; Dubois B; Belliard S; Puel M; Thomas-Anterion C; Michon A; Martin C; Charbonnier F; Raux G; Camuzat A; Penet C; Mesnage V; Martinez M; Clerget-Darpoux F; Brice A; Frebourg T
    Am J Hum Genet; 1999 Sep; 65(3):664-70. PubMed ID: 10441572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate.
    Twomey C; McCarthy JV
    FEBS Lett; 2006 Jul; 580(17):4015-20. PubMed ID: 16814287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1.
    Boutajangout A; Leroy K; Touchet N; Authelet M; Blanchard V; Tremp G; Pradier L; Brion JP
    Neurosci Lett; 2002 Jan; 318(1):29-33. PubMed ID: 11786218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease?
    Anderton BH; Dayanandan R; Killick R; Lovestone S
    Mol Med Today; 2000 Feb; 6(2):54-9. PubMed ID: 10652477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis.
    Zhang Z; Hartmann H; Do VM; Abramowski D; Sturchler-Pierrat C; Staufenbiel M; Sommer B; van de Wetering M; Clevers H; Saftig P; De Strooper B; He X; Yankner BA
    Nature; 1998 Oct; 395(6703):698-702. PubMed ID: 9790190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life.
    Snider BJ; Norton J; Coats MA; Chakraverty S; Hou CE; Jervis R; Lendon CL; Goate AM; McKeel DW; Morris JC
    Arch Neurol; 2005 Dec; 62(12):1821-30. PubMed ID: 16344340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer's disease.
    Jacquemont ML; Campion D; Hahn V; Tallaksen C; Frebourg T; Brice A; Durr A
    J Med Genet; 2002 Feb; 39(2):E2. PubMed ID: 11836371
    [No Abstract]   [Full Text] [Related]  

  • 14. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.
    Pei JJ; Tanaka T; Tung YC; Braak E; Iqbal K; Grundke-Iqbal I
    J Neuropathol Exp Neurol; 1997 Jan; 56(1):70-8. PubMed ID: 8990130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease.
    Raux G; Gantier R; Martin C; Pothin Y; Brice A; Frebourg T; Campion D
    Hum Mutat; 2000 Jul; 16(1):95. PubMed ID: 10874324
    [No Abstract]   [Full Text] [Related]  

  • 16. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
    Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance.
    Balaraman Y; Limaye AR; Levey AI; Srinivasan S
    Cell Mol Life Sci; 2006 Jun; 63(11):1226-35. PubMed ID: 16568235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation.
    Baum L; Hansen L; Masliah E; Saitoh T
    Mol Chem Neuropathol; 1996; 29(2-3):253-61. PubMed ID: 8971700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress.
    Vestling M; Wiehager B; Tanii H; Cowburn RF
    J Neurosci Res; 2001 Nov; 66(3):448-56. PubMed ID: 11746362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical phenotype of G206D mutation in the presenilin 1 gene in pathologically confirmed familial Alzheimer's disease.
    Wu YY; Cheng IH; Lee CC; Chiu MJ; Lee MJ; Chen TF; Hsu JL
    J Alzheimers Dis; 2011; 25(1):145-50. PubMed ID: 21335660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.